These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8318030)

  • 1. Beneficial effects of interferon-alpha 2b in Behçet's disease.
    Durand JM; Kaplanski G; Telle H; Soubeyrand J; Paulo F
    Arthritis Rheum; 1993 Jul; 36(7):1025-6. PubMed ID: 8318030
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease.
    Stuebiger N; Koetter I; Zierhut M
    Br J Ophthalmol; 2000 Dec; 84(12):1437-8. PubMed ID: 11186866
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon-alpha 2b for refractory ocular Behçet's disease.
    Feron EJ; Rothova A; van Hagen PM; Baarsma GS; Suttorp-Schulten MS
    Lancet; 1994 Jun; 343(8910):1428. PubMed ID: 7910903
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon-alpha 2b for refractory ocular Behçet's disease.
    Durand JM; Soubeyrand J
    Lancet; 1994 Jul; 344(8918):333. PubMed ID: 7914275
    [No Abstract]   [Full Text] [Related]  

  • 5. Pityriasis rosea in a patient with Behçet's disease treated with interferon alpha 2A.
    Durusoy C; Alpsoy E; Yilmaz E
    J Dermatol; 1999 Apr; 26(4):225-8. PubMed ID: 10343467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.
    Kötter I; Zierhut M; Eckstein A; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Kanz L; Stübiger N
    Adv Exp Med Biol; 2003; 528():521-3. PubMed ID: 12918755
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of interferon-alpha in Behçet's disease--review of the literature and possible mechanisms of action.
    Kötter I; Günaydin I; Treusch M; Zierhut M; Kanz L; Stübiger N
    Adv Exp Med Biol; 2003; 528():503-9. PubMed ID: 12918753
    [No Abstract]   [Full Text] [Related]  

  • 8. HHV8 associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon alpha.
    Kötter I; Aepinus C; Graepler F; Gärtner V; Eckstein AK; Stübiger N; Kaskas B; Zierhut M; Bültmann B; Kandolf R; Kanz L
    Ann Rheum Dis; 2001 Jan; 60(1):83-6. PubMed ID: 11114291
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to allegations and some considerations on interferon treatment in Behçet's disease.
    Demiroglu H
    Br J Ophthalmol; 2004 Feb; 88(2):312. PubMed ID: 14736807
    [No Abstract]   [Full Text] [Related]  

  • 10. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
    Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
    Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interferon and Behcet's disease. Therapeutic exception or loss of chance?].
    Wechsler B
    Rev Med Interne; 2000 Sep; 21(9):745-6. PubMed ID: 11039169
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of interferon-alpha on lymphocyte subpopulations in Behçet's disease.
    Treusch M; Stübiger N; Vonthein R; Baur M; Koch S; Günaydin I; Kanz L; Zierhut M; Kötter I
    Adv Exp Med Biol; 2003; 528():533-5. PubMed ID: 12918758
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term effects of interferon alpha 2A treatment in Behçet's disease.
    Boyvat A; Sişman-Solak C; Gürler A
    Dermatology; 2000; 201(1):40-3. PubMed ID: 10971058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifocal ERG changes in patients with ocular Behçet's disease during therapy with interferon alpha 2a.
    Stübiger N; Besch D; Deuter CM; Zierhut M; Kötter I
    Adv Exp Med Biol; 2003; 528():529-32. PubMed ID: 12918757
    [No Abstract]   [Full Text] [Related]  

  • 15. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.
    Demiroglu H; Ozcebe OI; Barista I; Dündar S; Eldem B
    Lancet; 2000 Feb; 355(9204):605-9. PubMed ID: 10696980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease.
    Krause L; Turnbull JR; Torun N; Pleyer U; Zouboulis CC; Foerster MH
    Adv Exp Med Biol; 2003; 528():511-9. PubMed ID: 12918754
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
    Zouboulis CC; Orfanos CE
    Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha in the management of patients with Behçet's disease.
    Yang DS; Taylor SR; Lightman SL
    Br J Hosp Med (Lond); 2008 Oct; 69(10):575-9. PubMed ID: 18949947
    [No Abstract]   [Full Text] [Related]  

  • 19. Low dose interferon-alpha to treat Behçet's disease.
    Thirion M; Miceli-Richard C; Labetoulle M; Mariette X
    Clin Exp Rheumatol; 2007; 25(5):791. PubMed ID: 18078636
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.
    Kötter I; Eckstein AK; Stübiger N; Zierhut M
    Br J Ophthalmol; 1998 May; 82(5):488-94. PubMed ID: 9713053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.